Multiple myeloma · 5 regimens
Cost vs Efficacy · 4 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Thalidomide and Dexamethasone (TD) Variant #06 | — | R 64 543 | 30d | 28.2 mo | 110.0 mo | 18 | R 678 160 PFS proxy | 1 |
Bortezomib and Dexamethasone (Vd) Variant #01 | — | R 7 456 | 28d | 14.7 mo | — | 8 | R 59 651 PFS proxy | — |
Bortezomib and Prednisone (VP) Variant #01 | — | R 6 851 | 90d | — | — | ~12 | ~R 82 212 indirect | — |
Lenalidomide and Dexamethasone (Rd) Variant #02 | — | R 4 309 | 28d | 25.5 mo | 63.8 mo | 40 | R 132 764 PFS proxy | 15 |
Lenalidomide and Prednisone (RP) Variant #02 | — | R 2 182 | 28d | ~37.5 mo | — | ~5 | ~R 10 910 PFS proxy · indirect | 1 |
5 of 5 regimens shown